Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 1
2019 3
2020 4
2021 4
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions.
Deal CE, Richards AF, Yeung T, Maron MJ, Wang Z, Lai YT, Fritz BR, Himansu S, Narayanan E, Liu D, Koleva R, Licht S, Hsiao CJ, Rajlic IL, Koch H, Kleyman M, Pulse ME, Weiss WJ, Doering JE, Lindberg SK, Mantis NJ, Carfi A, Plante OJ. Deal CE, et al. Among authors: himansu s. Cell Rep Med. 2023 Nov 21;4(11):101253. doi: 10.1016/j.xcrm.2023.101253. Epub 2023 Nov 1. Cell Rep Med. 2023. PMID: 37918405 Free PMC article.
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection.
Ronk AJ, Lloyd NM, Zhang M, Atyeo C, Perrett HR, Mire CE, Hastie KM, Sanders RW, Brouwer PJM, Saphire EO, Ward AB, Ksiazek TG, Alvarez Moreno JC, Thaker HM, Alter G, Himansu S, Carfi A, Bukreyev A. Ronk AJ, et al. Among authors: himansu s. Nat Commun. 2023 Sep 12;14(1):5603. doi: 10.1038/s41467-023-41376-6. Nat Commun. 2023. PMID: 37699929 Free PMC article.
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.
Zhang P, Falcone S, Tsybovsky Y, Singh M, Gopan V, Miao H, Seo Y, Rogers D, Renzi I, Lai YT, Narayanan E, Stewart-Jones G, Himansu S, Carfi A, Fauci AS, Lusso P. Zhang P, et al. Among authors: himansu s. Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2305896120. doi: 10.1073/pnas.2305896120. Epub 2023 Jul 10. Proc Natl Acad Sci U S A. 2023. PMID: 37428933 Free PMC article.
Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice.
Melzi E, Willis JR, Ma KM, Lin YC, Kratochvil S, Berndsen ZT, Landais EA, Kalyuzhniy O, Nair U, Warner J, Steichen JM, Kalyuzhniy A, Le A, Pecetta S, Perez M, Kirsch K, Weldon SR, Falcone S, Himansu S, Carfi A, Sok D, Ward AB, Schief WR, Batista FD. Melzi E, et al. Among authors: himansu s. Immunity. 2022 Nov 8;55(11):2168-2186.e6. doi: 10.1016/j.immuni.2022.09.003. Epub 2022 Sep 29. Immunity. 2022. PMID: 36179690 Free PMC article.
Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.
Willis JR, Berndsen ZT, Ma KM, Steichen JM, Schiffner T, Landais E, Liguori A, Kalyuzhniy O, Allen JD, Baboo S, Omorodion O, Diedrich JK, Hu X, Georgeson E, Phelps N, Eskandarzadeh S, Groschel B, Kubitz M, Adachi Y, Mullin TM, Alavi NB, Falcone S, Himansu S, Carfi A, Wilson IA, Yates JR 3rd, Paulson JC, Crispin M, Ward AB, Schief WR. Willis JR, et al. Among authors: himansu s. Immunity. 2022 Nov 8;55(11):2149-2167.e9. doi: 10.1016/j.immuni.2022.09.001. Epub 2022 Sep 29. Immunity. 2022. PMID: 36179689 Free PMC article.
Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.
August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, Han S, Lecerf JM, Tomassini JE, Hard M, Ptaszek LM, Crowe JE, Zaks T. August A, et al. Among authors: himansu s. Nat Med. 2022 May;28(5):1095-1096. doi: 10.1038/s41591-022-01817-z. Nat Med. 2022. PMID: 35449420 Free PMC article. No abstract available.
Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.
Loomis RJ, DiPiazza AT, Falcone S, Ruckwardt TJ, Morabito KM, Abiona OM, Chang LA, Caringal RT, Presnyak V, Narayanan E, Tsybovsky Y, Nair D, Hutchinson GB, Stewart-Jones GBE, Kueltzo LA, Himansu S, Mascola JR, Carfi A, Graham BS. Loomis RJ, et al. Among authors: himansu s. Front Immunol. 2021 Dec 8;12:772864. doi: 10.3389/fimmu.2021.772864. eCollection 2021. Front Immunol. 2021. PMID: 34956199 Free PMC article.
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, Hu Z, Follmann D, Lin Y, Miao H, Schmeisser H, Rogers D, Falcone S, Elbashir SM, Presnyak V, Bahl K, Prabhakaran M, Chen X, Sarfo EK, Ambrozak DR, Gautam R, Martin MA, Swerczek J, Herbert R, Weiss D, Misamore J, Ciaramella G, Himansu S, Stewart-Jones G, McDermott A, Koup RA, Mascola JR, Finzi A, Carfi A, Fauci AS, Lusso P. Zhang P, et al. Among authors: himansu s. Nat Med. 2021 Dec;27(12):2234-2245. doi: 10.1038/s41591-021-01574-5. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887575
23 results